Characterizing up to 2 years of ofatumumab onboarding and utilization among real-world relapsing multiple sclerosis patients in Australia the EAFToS Secondary Use of Data Study

被引：0

作者：

van der Walt, Anneke ^{[1
]}

Broadley, Simon ^{[2
]}

Burton, Jason ^{[3
]}

Hardy, Todd ^{[4
]}

Kemp, Clare ^{[5
]}

Walker, Rob ^{[5
]}

Berry, Patricia ^{[5
]}

Martel, Kate ^{[5
]}

Lam, Lien ^{[5
]}

Nelson, Morag ^{[5
]}

机构：

[1] Monash Univ, Dept Neurosci, Cent Clin Sch, Melbourne, Australia

[2] Griffith Univ, Sch Med, Gold Coast Campus, Southport, Australia

[3] Nexus Neurol, Murdoch, Australia

[4] Univ Sydney, Concord Hosp, Sydney, Australia

[5] Novartis Pharmaceut Australia, Sydney, Australia

来源：

关键词：

D O I：

暂无

中图分类号：

R74 [神经病学与精神病学];

学科分类号：

摘要：

P746/1502

引用

页码：641 / 642

页数：2